🇺🇸North America

Medical Device Regulation in United States

The U.S. FDA regulates medical devices under the Federal Food, Drug, and Cosmetic Act. The Center for Devices and Radiological Health (CDRH) oversees pre-market review and post-market surveillance using a risk-based three-class system. The FDA is one of the most influential regulatory bodies globally.

FrameworkFD&C Act / 21 CFR Parts 800–898 / QMSR (21 CFR Part 820)
Classification systemClass I / Class II / Class III
Primary agencyFDA/CDRH
RegionNorth America
References tracked832
Updates this year53

Sources Tracked by Qalico

Qalico continuously monitors 832 references across guidelines, regulations, and standards for United States.

Regulations

FDA 21 CFR154 refs

Guidelines

FDA Guidances670 refs
IMDRF — Consultations1 ref
IMDRF — Documents3 refs
MDSAP — Documents4 refs

Device Classification

Class IClass IIClass III

Class I (low risk, general controls only): e.g., bandages, tongue depressors — most are exempt from 510(k). Class II (moderate risk, special controls): e.g., infusion pumps, powered wheelchairs — typically requires 510(k). Class III (high risk, life-supporting): e.g., pacemakers, heart valves — requires Premarket Approval (PMA).

Official classification guidance →

Standards & Key Principles

Applicable Standards

ISO 13485:2016 (QMS)ISO 14971:2019 (Risk Management)IEC 62304:2006+A1 (Software Lifecycle)IEC 60601-1 (Electrical Safety)21 CFR Part 820 / QMSR

Key Principles

  • Risk-based classification determines the premarket pathway
  • Substantial equivalence (510k) or safety & effectiveness (PMA)
  • Quality Management System aligned with ISO 13485
  • Unique Device Identification (UDI) in GUDID database
  • IMDRF and GHTF harmonization principles
  • Clinical evidence proportional to device risk

Pre-Market Requirements

510(k) – Premarket Notification

Required for most Class II devices. Demonstrates substantial equivalence to a legally marketed predicate device. FDA review target: 90 days.

PMA – Premarket Approval

Required for Class III devices. Full scientific review of safety and effectiveness with clinical data. Review target: 180 days.

De Novo Request

For novel low-to-moderate risk devices without a predicate. Establishes a new device type with special controls. Can become a predicate for future 510(k)s.

Exempt Devices

Most Class I devices are exempt from premarket notification but must comply with general controls: labeling, establishment registration, device listing, and GMP.

Post-Market Requirements

Medical Device Reporting (MDR)

Manufacturers must report device-related deaths and serious injuries within 30 days (5 days for urgent situations).

Unique Device Identification (UDI)

Devices must carry a UDI label and be registered in the GUDID database for traceability.

Post-Market Surveillance (PMS)

Systematic ongoing collection of post-market data. Class III and some Class II require Post-Market Surveillance Reports.

Quality System / CAPA

Ongoing compliance with QMSR including corrective and preventive actions, complaint handling, and design controls.

International Recognition & Reliance

Canada

Health Canada accepts FDA-cleared/approved data to support Medical Device Licence applications.

Australia

TGA accepts FDA marketing authorization as supporting evidence under the MDSAP framework.

Japan

PMDA references FDA decisions as supporting data for some Class II–III devices.

Stay on top of regulatory changes in United States

Qalico monitors publications from FDA/CDRH in real time, surfacing updates that matter to your device category — so your team never misses a critical change.